Drug intelligence / Profile preview

AM-168

Development stage: Preclinical
Lead developer: Academab Biomedical
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics

Overview

AM-168 is a fully human monoclonal antibody developed by AcadeMab Biomedical Inc. that targets the HER3 (ErbB3) receptor. It acts as a HER3 antagonist by blocking the binding of the ligand heregulin (HRG) to the receptor, thereby inhibiting the HER3 signaling pathway. HER3 is often overexpressed or co-activated in various cancers, contributing to tumor growth and resistance to other HER-family targeted therapies. AM-168 is currently in the discovery stage for potential application in cancer treatment.

Targets

ERBB3 (Erb-b2 receptor tyrosine kinase 3)

Beyond the preview

Go deeper on AM-168.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AM-168.

Explore the full profile